openPR Logo
Press release

Exclusive interview with conference speaker Che Connon released ahead of SMi’s Ophthalmic Drugs Conference

10-29-2019 01:10 PM CET | Health & Medicine

Press release from: SMi Group

Ophthalmic Drugs Conference 2019

Ophthalmic Drugs Conference 2019

SMi has released an exclusive interview with industry expert Che Connon, Professor of Tissue Engineering at Newcastle University, ahead of the upcoming Ophthalmic Drugs conference which takes place in London on 19th-20th November 2019.

As Europe’s leading Ophthalmic Drugs conference, this year’s event will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug domain.

Professor Connon’s research team seeks to engineer functional replacement and temporary 'bridge' tissues using a modular approach while also developing model systems to study physiological and pathophysiological corneal tissue formation. He is currently working with smart (cell responsive) biomaterials, characterizing the mechanical and geometric environment of the corneal stem cell niche and 3D printing the corneal stroma.

Here is a snapshot of what was discussed:

The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?
“Significant developments I have noticed include self-therapy for the cornea. The advances in cell therapy for corneal limbal stem cell treatment have been particularly significant with the fact that it has authorisation and is pushing ahead.”

What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?
“My interest is in cell therapy - cellular drugs, cells as a drug and how do you list significant challenges in and around the logistics of moving that product around. Also, in the future how do you make enough cells to address all the predicted needs and patients.”

The full version of the interview and event brochure are available to download online at:
www.ophthalmicdrugs.com/openPR9

Che Connon will be presenting on “Biomechanical modulation therapy: A druggable alternative to corneal stem cell transplantation.”
• Chemical burns to the ocular surface affect tissue stiffness
• The corneal stem cell niche has specific biomechanical requirements to retain stem cells
• Restoring the correct biomechanical state of the corneal stem cell niche following wounding improve healing
• Biomechanical modulation therapy is a new treatment paradigm for corneal epithelial wounds

Ophthalmic Drugs 2019
Main Conference: 19th – 20th November 2019
Pre-Conference Focus Day: 18th November 2019
Location: Copthorne Tara Hotel, London, UK

---END---

For sponsorship, exhibition and branding enquiries contact Alia Malick +44 (0)20 7827 6168 / amalick@smi-online.co.uk

For all media enquiries contact Neill Howard +44 (0) 207 827 6164 / nhoward@smi-online.co.uk

SMi Group
India House
45 Curlew Street
London
SE1 2ND

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive interview with conference speaker Che Connon released ahead of SMi’s Ophthalmic Drugs Conference here

News-ID: 1857981 • Views:

More Releases from SMi Group

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,

All 5 Releases


More Releases for Ophthalmic

Ophthalmic Trial Frames Market Depth Survey Report 2019| Topcon, Luneau, Takagi …
Ophthalmic trial frames are adjustable frames that are used to hold lenses during refraction test and during retinoscopy test of the eye. Ophthalmic trial frames are eyeglasses designed in such a way that different lenses can be inserted and can be used to correct refractive errors of vision. Ophthalmic trial frames are light weight, adjustable and should have a comfortable nose resting and can be adjusted to allow accurate centering.
Ophthalmic Eye Shield Market Segmentation By Material type Aluminium Ophthalmic …
Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization,
04-08-2019 | Health & Medicine
Fact.MR
Eye socket Implants Market Offered in New Research Forecasted through 2026 // Ke …
The global Eye socket Implants market is expected to see remarkable growth in the forecast period due to increase in work-related eye injuries. Increase in the number of patients drives the overall eye socket implants market. Higher adoption of surgeries in higher economic regions propels the Eye socket Implants Market. Others factors like increasing prevalence and incidence of eye-related disease, changing lifestyle pattern are the factors which are fueling the
Ophthalmic Surgical Technologies Market - Femtosecond Systems Likely to Dominate …
The global ophthalmic surgical technologies market is driven mainly by the growing funding in the healthcare sector and the rising awareness about eye care, added to the rising prevalence of eye diseases. The ophthalmic surgical technologies market has enjoyed a supportive regulatory and economic structure in most regions in the recent past and is thus likely to continue on the strong growth trajectory it has exhibited in recent years. Increasing
Ophthalmic Lasers Market: Demand for Ophthalmic Lasers to Remain Higher in North …
Lasers have become an essential part of treatment modality for a number of practicing ophthalmologist. Ophthalmic lasers have gained prominence with the popularity of laser-assisted surgeries for rectifying nearsightedness or myopia. The increasing incidence of ophthalmic disorders and rise in geriatric population in various regions have boosted the application of different types of lasers in treating specific eye problems and improving vision. Technological advances have significantly increased the safety and
Ophthalmic Ultrasound Device Market: A-scan Ophthalmic Ultrasound Devices High i …
Global Ophthalmic Ultrasound Device Market: Snapshot The constantly increasing percentage of the geriatric population across the world is widely considered as the primary factor augmenting the demand for ophthalmic ultrasound devices. The high geriatric population is directly linked to the increasing patient count for ocular diseases and disorders, along with chronic diseases such as diabetes. The increasing levels of pollution are also responsible for the high volume of ovular disorders across